Former FDA Head Steve Hahn Joins BreakBio, a Personalized Cancer Drug Company, as Advisor
MIAMI, Oct. 26, 2026 /PRNewswire/ -- BreakBio, a biotech company developing personalized drugs for cancer, today announced that Stephen M....
immunotherapy
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience,...
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a...
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy...
Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer
Faster and higher expansion of tumor-targeting CD8 T cells associated with longer overall survival in previously treated mismatch repair proficient...
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific...
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief...
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Nes-Ziona, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company...
‘Granite Gives Pink’ Raises $583K for Breast Cancer Research Foundation
Employee-Led Fundraiser Builds on Record-Breaking Support for Breast Cancer ResearchQUINCY, Mass., Oct. 22, 2026 /PRNewswire/ -- Granite Telecommunications, one of...
GLOBAL STREAMERS TURN WORLD GAMING DAY INTO A GLOBAL FIGHT FOR CANCER SUPPORT WITH LA ROCHE-POSAY USA ON DISCORD
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- During World Gaming Day today, La Roche-Posay will host a new edition of its...
GLOBAL STREAMERS TURN WORLD GAMING DAY INTO A GLOBAL FIGHT FOR CANCER SUPPORT WITH LA ROCHE-POSAY USA ON DISCORD
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- During World Gaming Day today, La Roche-Posay will host a new edition of its...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
Ad hoc announcement pursuant to Art. 53 LRBasel, 22 October 2026 Roche continues strong momentum in the third quarter with...
Avance Clinical to Meet European Biotechs at ESMO Congress 2026 and Appoints Wendy Hamon as Senior Vice President, Oncology Center of Excellence
Executive Medical Director Dr George Peoples to discuss oncology programs from preclinical through Phase II in Madrid Wendy Hamon Wendy...
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”)...
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
Extending the Company's Immunologically Cold Tumor Strategy into Colorectal CancerNANJING, China , Oct. 16, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads...
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track...
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will...
Siren Biotechnology Appoints Former FDA CBER Oncology Branch Chief to Clinical and Scientific Advisory Board
Veteran oncology regulator brings more than 25 years of FDA experience as Siren advances SRN-101 into clinical developmentSAN FRANCISCO, Oct....
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma
Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCC FORT LEE, N.J., Oct. 14, 2026 (GLOBE...
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key...